RedHill Biopharma Ltd. (RDHL)
| Market Cap | 5.01M +100.4% |
| Revenue (ttm) | 286,000 -95.1% |
| Net Income | -429,000 |
| EPS | -0.14 |
| Shares Out | 5.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,854 |
| Open | 0.9200 |
| Previous Close | 0.9350 |
| Day's Range | 0.9100 - 1.0000 |
| 52-Week Range | 0.7101 - 3.3100 |
| Beta | 5.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 27, 2026 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; ... [Read more]
Financial Performance
Financial StatementsNews
RedHill Biopharma Slides: Corporate presentation
RedHill Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease
RedHill Biopharma (RDHL) announced new in vitro testing results demonstrating RHB-204’s comparability to RHB-104 in Mycobacterium avium subspecies paratuberculosis, or MAP, killing efficacy. Oral RHB-...
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium ...
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partners...
RedHill Biopharma announces presentation of preclinical data on opaganib at AACR
RedHill Biopharma (RDHL) announced the independent presentation of new preclinical data at the 2026 American Association for Cancer Research, or AACR, Annual Meeting, showing positive effects of opaga...
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on thera...
RedHill Biopharma Slides: Corporate presentation
RedHill Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
RedHill Biopharma announces full sales and operational launch of Talicia
RedHill Biopharma (RDHL) announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings, or THI, and Cumberland Pharmaceuticals (...
Joint U.S. Commercialization of RedHill's Talicia® Commences
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...
RedHill Biopharma announces development progress for RHB-102
RedHill Biopharma (RDHL) announced development progress for RHB-102 in multiple GI indications, including its development, via the accelerated FDA 505(b)(2) route, as a once-daily oral ondansetron the...
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis ...
RedHill Biopharma announces in vivo results on opaganib, venetoclax
RedHill Biopharma (RDHL) announced positive in vivo results, indicating that opaganib combined with venetoclax reduces Chronic Lymphocytic Leukemia, CLL, cells by half compared to controls, and furthe...
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic...
RedHill Biopharma regains compliance with Nasdaq equity requirement
RedHill Biopharma (RDHL) announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market that the Company has regained compliance with the stockholders’ equity requirement s...
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill says $10.5M New York Supreme Court judgment now final for enforcement
RedHill Biopharma (RDHL) announced that the New York Supreme Court’s summary judgment in favor of RedHill against Kukbo Co. Ltd is now final and eligible for enforcement and foreign recognition,…
RedHill Biopharma announces $10.5M New York Supreme Court judgment win
RedHill Biopharma (RDHL) announced that the New York Supreme Court’s summary judgment in favor of RedHill against Kukbo Co. is now final and eligible for enforcement and foreign recognition, with…
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Receives Nasdaq Staff Determination Notification
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for ...
RedHill Biopharma signs strategic partnership with Cumberland
RedHill Biopharma (RDHL) announced the signing of a strategic partnership with Cumberland Pharmaceuticals (CPIX), a specialty pharmaceuticals company with a strong gastrointestinal market presence, wh...
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX),...
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment an...
RedHill Biopharma wins New York Supreme Court appeal
RedHill Biopharma (RDHL) announced that The New York Supreme Court has, on appeal, upheld its original summary judgment ruling and award in favor of RedHill, unequivocally dismissing, once again, the…
RedHill Biopharma wins New York Supreme Court appeal
RedHill Biopharma (RDHL) announced that The New York Supreme Court has, on appeal, upheld its original summary judgment ruling and award in favor of RedHill, unequivocally dismissing, once again, the…
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defense again, f...